The stream · Daily digest
The stream: Saturday, November 14, 2026
1 brief, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 1
-
Lilly presents new data on Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026
Lilly will present Phase 2 data showing EloraTZP achieved an average weight loss of 54.1 lbs (23.3%) and lowered A1C by 2.9% in adults with obesity or overweight and type 2 diabetes. Retatrutide results from TRIUMPH trials demonstrated reductions in apnea-hypopnea index and knee osteoarthritis pain up to 36.1 events per hour and 4.5 points, respectively.
Source: Company press release (PR Newswire), November 14, 2026